𝐍𝐨𝐯𝐞𝐥 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐓𝐮𝐛𝐞𝐫𝐜𝐮𝐥𝐨𝐬𝐢𝐬 𝐚𝐧𝐝 𝐨𝐭𝐡𝐞𝐫 𝐌𝐲𝐜𝐨𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐚𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 (𝐈𝐓𝐇𝐄𝐌𝐘𝐂)
The Combine Group is delighted to announce our involvement in yet another project funded under the Horizon Europe Program:
Novel Immunotherapies for Tuberculosis and other Mycobacterial Diseases (ITHEMYC)
💊 This venture is a significant opportunity to apply innovative solutions in silico modelling to facilitate both in vitro and in vivo preclinical progression and predict the therapeutic efficacy in the clinical stages of Tuberculosis.
🤳 Stay updated on the latest developments of this cutting-edge project by following us on social media: